XENON PHARMACEUTICALS INC. Debt Securities, Available-for-sale
XENON PHARMACEUTICALS INC. (XENE) had Debt Securities, Available-for-sale of $1.13 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale $1.13B.
- 2026-03-31: Debt Securities, Available-for-sale $793.75M.
- 2025-12-31: Debt Securities, Available-for-sale $386.88M.
- 2025-09-30: Debt Securities, Available-for-sale $450.74M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $1.13B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $793.75M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $386.88M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $450.74M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $489.46M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $574.47M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $611.69M 10-K · filed 2026-02-26 |
| 2024-09-30 | $715.71M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $713.86M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $826.54M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $768.36M 10-K · filed 2025-02-27 |
| 2023-09-30 | $499.72M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $493.87M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $447.61M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $386.88M 10-K · filed 2024-02-29 |
| 2022-09-30 | $293.14M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |